Is RU58841 The Most Effective Hair Regrowth Treatment? | Why?

The impact of hair loss is widespread. According to a 2014 survey by the International Society of Hair Restoration Surgery, around 35 million men and approximately 21 million women in the U.S. experience some form of hair loss. With over 320 million people in the country, and considering that at least 20% are under 30 years old, it means that more than 1 in 5 Americans are dealing with hair loss, with men being more commonly affected.

As age increases, so does the likelihood of experiencing hair loss, particularly for men. By the age of 35, about 40% of men have visible signs of hair loss, and this percentage rises to 65% by the age of 60. This suggests that nearly half of men in their late forties or early fifties are grappling with noticeable hair loss.

Interestingly, the numbers for women are even higher. Another survey indicates that around 40% of women experience hair loss by the age of 40. By the age of 60, approximately 80% of women face some degree of noticeable hair loss, highlighting the widespread nature of this concern among both men and women.

So, scientists have been looking for good solutions to this problem for a long time. One hopeful option that's caught our attention is RU58841. People are excited about it, thinking it might be the answer to regrowing hair. But here's the big question: Is RU58841 the very best way to make hair grow back? To figure this out, we're going to explore the facts, studies, and stories of people who've tried RU58841. 

The Origin of RU58841

RU58841 originated from the efforts of the French pharmaceutical company Roussel Uclaf in the 1970s. Although it was produced in the 1980s, most of its developmental research occurred in the 1990s. The primary goal was to create a potent topical medication for managing acne and androgenic alopecia while minimizing systemic side effects common in other anti-androgens.

During trials, conducted on rats and hamsters, even small doses as low as 0.001 milligrams demonstrated significant local effects. Higher doses, up to 0.01 milligrams, still remained localized, a favourable outcome for researchers. Over time, various companies acquired and relinquished rights to RU58841. Ultimately, ProStraken obtained full rights, renaming it PSK3841.

ProStraken conducted two human clinical trials, but the results were not published. A phase 3 trial was planned but never executed due to ProStraken's acquisition by Kyowa Kurin, leading to project cancellation for financial reasons.

Although initial results seemed promising, no further human studies were published in peer-reviewed journals for over a decade. Some monkey-based studies indicated that RU58841 at 5% was effective, showing a 103% increase in hair growth compared to 88% for finasteride. Finasteride lowered serum DHT levels by 70%, while RU58841 had no impact.

Another study evaluated RU58841's effectiveness on human hair transplanted onto nude mice skin. However, due to the lack of direct human studies for more than a decade, the FDA has not approved RU58841 for managing any condition.

What RU58841 Exactly Is?

RU58841, also known as PSK-3841 or HMR-3841, is a non-steroidal anti-androgen compound. It has been studied for its potential use in treating androgenic alopecia (male-pattern baldness) and other conditions related to androgen activity. Unlike some other anti-androgens, RU58841 is designed to be applied topically (externally) rather than taken orally.

The compound works by binding to androgen receptors in the scalp, thereby blocking the effects of dihydrotestosterone (DHT), which is a hormone implicated in hair loss. DHT is derived from testosterone and is believed to contribute to the miniaturization of hair follicles in individuals genetically predisposed to androgenetic alopecia.

It's important to note that while there is ongoing research on RU58841 and similar compounds, they have not been approved for medical use, and their safety and efficacy have not been fully established. As with any experimental or unapproved treatments, individuals should exercise caution and consult with healthcare professionals before using them. 

Why is DHT so Influential in Hair Loss?

The connection between dihydrotestosterone (DHT) and alopecia remains unclear. When testosterone is converted to DHT, a portion of it reaches the hair follicles and binds to androgen receptors on dermal papilla cells.

Upon binding, DHT initiates a series of events in the cell's cytoplasm that involves modifications to certain gene functions. The specific biochemical pathways influenced by DHT that hinder hair growth are not yet fully understood.

The compromised follicular cells undergo changes in the growth cycle, particularly a reduction in the duration of the anagen phase. This alteration causes the rapidly dividing cells responsible for forming new hair to prematurely cease their activity. Subsequently, with each successive hair growth cycle, the strands become progressively shorter and thinner, a phenomenon known as miniaturization.

Another common issue associated with a balding scalp is diminished blood circulation, impeding the delivery of essential nutrients such as vitamins, minerals, antioxidants, and proteins to the cells. This further shortens the average growth span of the follicles.

The effects of RU58841, a non-steroidal antiandrogen, on human hair production | A Study on Hair Regrowth

Hair loss is a common concern, and researchers are constantly exploring new treatments. A recent study was conducted to test RU58841’s effectiveness in promoting hair regrowth.

Scalp samples from balding men were transplanted onto female nude mice. To simulate androgen-dependent alopecia, all mice were treated with testosterone. The scalp samples were divided into two groups—one treated with RU58841 and the other with a control solution (ethanol).

Key Findings:

After 8 months of observation, distinct differences were seen between the two groups. In the control group treated with ethanol, only 7% of the 28 active follicles initiated a second hair cycle. Contrastingly, the group treated with RU58841 exhibited a more promising outcome. Out of the 29 active follicles, 28% showed a second cycle. Additionally, linear hair growth rates (LHGR) were notably higher in the RU58841-treated group.

Implications and Potential:

The study's findings suggest a positive correlation between RU58841 and human hair growth in balding samples grafted onto testosterone-conditioned nude mice. The observed follicle recycling and increased LHGR provide encouraging evidence for RU58841's potential in treating androgen-dependent alopecia.

In conclusion, RU58841 shows promise as a viable option for those seeking hair regrowth solutions. While the study is a significant step forward, researchers emphasize the need for further investigation through clinical trials to fully evaluate RU58841's efficacy and safety in treating androgen-dependent alopecia. The results inspire hope for individuals grappling with the challenges of hair loss. Source 

Hair Regrowth: Finasteride vs. RU58841 | Study 2

In a study published in the Journal of Dermatology, researchers Uno et al compared the effects of two antiandrogens—oral finasteride and topical RU58841—on follicular growth and hormone levels in balding macaques, providing valuable insights into potential treatments for hair loss.

The study focused on 20 macaques, whose bald scalps resemble the pattern seen in men with hair loss. To assess follicular regrowth, the researchers administered finasteride (1mg/kg/day) orally to one group of macaques and a placebo to another group. Simultaneously, RU58841 was topically applied to a different set of macaques. Skin biopsies were taken at different intervals: zero and six months for finasteride, and zero and four months for RU58841.

Results:

Follicular Growth:

• In the finasteride group, an average increase of 88% in anagen (healthy) follicles compared to vellus (miniaturized) follicles was observed.
• Remarkably, the RU58841 group exhibited a staggering 103% increase, surpassing all other treatment groups after just two months.

Hormone Levels:

• Finasteride led to a decrease in DHT levels and an increase in testosterone levels, aligning with its mechanism of action.
• In contrast, RU58841 showed no significant changes in DHT and testosterone levels.

The study's findings suggest that blocking androgen receptors, as achieved by RU58841, is more effective in promoting hair regrowth than systemically targeting the 5-alpha reductase enzyme, as done by finasteride. This insight opens up new possibilities for antiandrogen treatments for individuals experiencing hair loss. However, further research and clinical studies are necessary to validate these promising early results.

RU58841: Dose-Dependent and Long-Term Effects on Hair Regrowth | Study 3

Building on the success of their initial study, Uno et al. went deeper into the potential of RU58841 as a treatment for hair regrowth. In this subsequent investigation, the researchers varied the dosage of RU58841 to assess its dose-dependent and long-term effects on hair regrowth in macaques.

Twenty macaques were divided into five groups, each receiving different dosages of RU58841 (5%, 3%, 1%, 0.5%), while one group served as a placebo. The solutions were applied topically once per day for a duration of 6 months. To evaluate long-term effects, a subset of macaques from the 5%, 0.5%, and placebo groups continued treatment for 12 to 24 months.

Key Findings

Dose-Dependent Results:

• The group treated with 5% RU58841 exhibited a marked increase in hair density, thickness, and length, noticeable as early as three months into treatment.
• After 5 months, there was an average two- to three-fold increase in the number of scalp follicles, with a higher proportion in the anagen growth phase.

Long-Term Effects:

• Macaques in the 5% group, undergoing long-term treatment, showed progressive hair growth continuously for 3-7 months.
• Notably, the gains achieved during treatment were maintained, but hair loss resumed approximately three months after treatment cessation.

Dosage Comparison:

• While noticeable growth occurred in other groups, none demonstrated results as promising as the 5% group. The 1% and 0.5% groups exhibited weaker effects.

The study concludes that a 5% topical application of RU58841 induced remarkable effects on hair and follicular regrowth within a short timeframe.

RU58841 vs. Finasteride and Minoxidil

There are several options exist for hair loss treatment, each with its unique mechanisms and outcomes. In this section, we will compare RU58841 with two commonly used treatments—finasteride and minoxidil.

RU58841 vs. Finasteride

• RU58841: Blocks androgen receptors directly.
• Finasteride: Inhibits the 5-alpha reductase enzyme and reduces DHT levels.

Advantages:

• RU58841 acts directly on androgen receptors, potentially offering a targeted and efficient approach.
• Finasteride is an FDA-approved oral medication widely used for androgenetic alopecia.

Disadvantages:

• RU58841's topical application may raise concerns about absorption and systemic effects.
• Finasteride may cause side effects such as sexual dysfunction in a small percentage of users.

RU58841 vs. Minoxidil

• RU58841: Targets androgen receptors to inhibit hair loss.
• Minoxidil: Promotes blood flow to the hair follicles to encourage growth.

Advantages:

• RU58841 focuses on hormonal factors, potentially addressing the root cause.
• Minoxidil is available over-the-counter and is easy to apply topically.

Disadvantages:

• RU58841's long-term safety is still under investigation.
• Minoxidil requires consistent, long-term use to maintain results.

Overall Considerations for RU58841

• Potential for targeted action on androgen receptors.
• Promising results in terms of follicular density and regrowth.
• Topical application may appeal to those averse to oral medications.

Disadvantages of RU58841:

• Limited long-term safety data.
• Absorption concerns with topical application.

Note: There have been no long-term studies conducted to assess the potential side effects of RU58851, leaving uncertainties about its adverse reactions. Information regarding side effects is primarily derived from online testimonials and existing knowledge of physiological processes. As is typical with pharmaceuticals, individual responses may vary.

Regrettably, some individuals who have experimented with this compound have reported experiencing systemic effects, some of which have been severe enough to necessitate discontinuation. Due to RU58851 being available for research purposes only in recent years, definitive conclusions about the side effects after prolonged use remain elusive.

Reported side effects include:

• Erectile dysfunction
• Reduced libido
• Chest pain
• Irregular heartbeat
• Low mood
• Fatigue
• Disrupted sleep
• Skin irritation

In summary, whether RU58841 is the best solution for hair regrowth is still uncertain. We don't have enough detailed studies on its side effects, so it's a bit unclear how safe it is. People share their experiences online, but everyone's reaction to the treatment can be different.

While many users say it helped them, others had to stop using it because of side effects. Because RU58841 has only been around for a short time for research, we don't know for sure what might happen if you use it for a long time.

So, when it comes to using RU58841 for hair regrowth, it seems promising but also has some unknowns. As more research is done, we might get a clearer picture of how well it works and if there are any risks.

If you have decided to give it a try? Don't forget to choose MV Supplement as your trusted supplier. We deliver RU58841 all over Europe to your doorstep!